华熙生物(688363) - 2021 Q1 - 季度财报

Financial Performance - Operating income surged by 111.12% to CNY 776,684,991.71 year-on-year[4] - Net profit attributable to shareholders rose by 41.05% to CNY 152,396,070.06 compared to the same period last year[4] - Basic earnings per share increased by 39.13% to CNY 0.32 compared to the previous year[4] - The diluted earnings per share also increased by 39.13% to CNY 0.32 compared to the same period last year[4] - The company reported a total comprehensive income of ¥146,780,617.07 for Q1 2021, compared to ¥106,631,501.44 in Q1 2020, an increase of 38%[23] - Net profit for Q1 2021 was ¥152,170,016.46, compared to ¥107,857,564.75 in Q1 2020, representing an increase of 41%[23] - Net profit for Q1 2021 reached RMB 190,018,097.99, compared to RMB 96,130,237.23 in Q1 2020, reflecting a 97.5% year-over-year growth[26] Assets and Liabilities - Total assets increased by 5.86% to CNY 6,052,083,651.60 compared to the end of the previous year[4] - Total current assets as of March 31, 2021, amounted to ¥3,611,908,426.03, a slight decrease from ¥3,663,573,835.42 in the previous year[16] - The company's total liabilities amounted to ¥876,111,216.19, up from ¥698,757,707.99, indicating an increase of approximately 25.5%[18] - Current liabilities decreased to ¥508,513,690.23 from ¥552,869,788.62, a decline of about 8.0%[18] - Total liabilities increased to ¥408,107,485.96 in Q1 2021 from ¥234,851,115.61 in Q1 2020, indicating a growth of 74%[21] - Total liabilities amounted to 698,757,707.99 RMB, a decrease of 65,272,309.62 RMB compared to the previous period[33] Cash Flow - Net cash flow from operating activities decreased by 56.16% to CNY 23,706,569.22 year-on-year[4] - The company reported a net cash flow from operating activities of RMB 23.71 million, down 56.16% from RMB 54.08 million in Q1 2020[12] - Cash flow from operating activities generated RMB 23,706,569.22 in Q1 2021, down from RMB 54,075,706.53 in Q1 2020[28] - The net cash flow from operating activities for Q1 2021 was -53,336,051.07 RMB, compared to 51,970,241.89 RMB in Q1 2020, indicating a significant decline[30] Research and Development - R&D expenditure as a percentage of operating income decreased by 2.84 percentage points to 5.01%[4] - Research and development expenses rose by 34.78% to RMB 38.94 million, driven by an increase in R&D personnel and related costs[12] - Research and development expenses for Q1 2021 were ¥38,941,793.02, compared to ¥28,891,796.36 in Q1 2020, marking a 35% increase[22] Shareholder Information - The total number of shareholders reached 26,024 by the end of the reporting period[7] - The largest shareholder, Huaxi Xinyu Investment Co., Ltd., holds 59.06% of the shares[7] Government Subsidies - The company reported a government subsidy of CNY 6,225,633.79 included in the current profit and loss[5] Operating Costs - The operating cost for Q1 2021 was RMB 165.47 million, reflecting a 96.37% increase from RMB 84.27 million in the same period last year[11] - Total operating costs for Q1 2021 were ¥592,233,529.05, up from ¥243,185,850.60 in Q1 2020, reflecting a 144% increase[22] - The total operating costs for Q1 2021 were RMB 156,759,746.43, up from RMB 91,696,361.58 in Q1 2020, indicating a 70.9% increase[25] Investments - The company completed the acquisition of 100% equity in Fost Biotech for RMB 290 million, with the share transfer registration completed on September 18, 2020[13] - The company’s investment income increased by 62.89% to RMB 10.02 million, attributed to returns from idle fund management[12] Employee Compensation - The company reported a significant increase in employee compensation payments, totaling 80,436,804.57 RMB in Q1 2021, compared to 49,621,529.75 RMB in Q1 2020[30]